Please assess the completion status of the following clinical trial:

Trial Title: Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Parkinson's Disease or Parkinson Plus Syndrome~* Subject is a male or female between the age of 50 and 95~* Subject will write the informed consent~Exclusion Criteria:~* History of stroke or/and trauma~* Signs of cerebrovascular pathology~* Brain tumor~* Severe unrelated neurological or physical disease

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 95 Years
- Healthy Volunteers: t

Study Arms:
- PD Parkinson´s Disrease (Type: None): We are studying the presence of alpha-synuclein in the epidermis and dermis besides the end nerve terminal. We have several reports until now, and we are following the study because we wish to convince the academic and scientific society over the utility of this study to be close to the molecular diagnosis of this kind of disease.
- AP Atypical Parkinsonism (Type: None): with neurodegenerative disease (proteinopathies) and secondary AP.
- Control group (Type: None): Subjects without neurodegenerative disease and apparently good health status with an age that matches the problems groups

Based on this trial design, predict the completion outcome and termination type (if applicable).